Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929822 · ClinicalTrials.gov registry record
Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- 32
- Enrollment target
NCT03929822: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03929822 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03929822 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.
Primary Outcome
The radiologist will interpret the low energy images and record their findings.
Interventions
- DIAGNOSTIC_TEST Contrast-Enhanced Spectral Mammography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2023-01-19 |
Why NCT03929822 stopped before completion
NCT03929822 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Contrast-Enhanced Spectral Mammography is the first listed.
NCT03929822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03929822 about?
NCT03929822 is a clinical study titled "Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis". The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.
What is the current status of trial NCT03929822?
This trial is currently terminated. The enrollment target is 32 participants. The study started on 2019-04-23. Estimated completion is 2023-01-19.
What interventions are being tested in trial NCT03929822?
The interventions under investigation include: Contrast-Enhanced Spectral Mammography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03929822?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI